Evaluating markers for the early detection of cancer: overview of study designs and methods.

PubWeight™: 2.10‹?› | Rank: Top 2%

🔗 View Article (PMID 16539089)

Published in Clin Trials on January 01, 2006

Authors

Stuart G Baker1, Barnett S Kramer, Martin McIntosh, Blossom H Patterson, Yu Shyr, Steven Skates

Author Affiliations

1: National Institutes of Health, Bethesda, MD, USA. sb16i@nih.gov

Articles citing this

Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst (2008) 6.79

Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol (2011) 3.53

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03

Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol (2011) 2.90

Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol (2009) 2.86

Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60

Personalized medicine using DNA biomarkers: a review. Hum Genet (2012) 1.49

Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst (2009) 1.24

Promoter methylation and the detection of breast cancer. Cancer Causes Control (2009) 1.18

Sample size for positive and negative predictive value in diagnostic research using case-control designs. Biostatistics (2008) 1.15

Bayesian inference for the lead time in periodic cancer screening. Biometrics (2007) 1.07

DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol (2013) 1.05

Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia (2008) 1.05

New paradigms in translational science research in cancer biomarkers. Transl Res (2012) 0.92

Biomarkers for Early Cancer Detection - Methodological Aspects. Breast Care (Basel) (2010) 0.90

Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma. Biomark Insights (2008) 0.88

Better cancer biomarker discovery through better study design. Eur J Clin Invest (2012) 0.84

On the assessment of the added value of new predictive biomarkers. BMC Med Res Methodol (2013) 0.82

Potential biomarkers for lung cancer screening. Transl Lung Cancer Res (2014) 0.80

Variations in discovery-based preeclampsia candidate genes. Clin Transl Sci (2012) 0.77

A simple method to combine multiple molecular biomarkers for dichotomous diagnostic classification. BMC Bioinformatics (2006) 0.76

Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. Cancer (2017) 0.75

Articles by these authors

(truncated to the top 100)

Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61

The case for early detection. Nat Rev Cancer (2003) 6.96

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45

The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43

A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13

Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol (2007) 4.06

Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 4.01

The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell (2012) 3.91

New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85

Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51

Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48

General framework for developing and evaluating database scoring algorithms using the TANDEM search engine. Bioinformatics (2006) 3.35

A suite of algorithms for the comprehensive analysis of complex protein mixtures using high-resolution LC-MS. Bioinformatics (2006) 3.32

Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01

MRMer, an interactive open source and cross-platform system for data extraction and visualization of multiple reaction monitoring experiments. Mol Cell Proteomics (2008) 2.89

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82

Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82

Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79

Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71

Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res (2003) 2.70

The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med (2007) 2.62

Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int (2004) 2.52

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38

Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26

Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26

Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res (2006) 2.20

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol (2008) 2.10

Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res (2006) 2.10

Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res (2005) 2.06

Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05

Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res (2007) 2.04

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00

Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis (2004) 1.87

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov (2011) 1.76

The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform (2012) 1.72

Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem Res Toxicol (2006) 1.69

Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68

Changes in vegetable and fruit consumption and awareness among US adults: results of the 1991 and 1997 5 A Day for Better Health Program surveys. J Am Diet Assoc (2002) 1.67

Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int (2004) 1.66

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64

Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol (2011) 1.63

Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer Inst (2002) 1.63

Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int (2013) 1.61

Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. PLoS One (2013) 1.61

Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res (2005) 1.61

Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61

Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60

DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest (2014) 1.59

National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56

Evidence Combination From an Evolutionary Game Theory Perspective. IEEE Trans Cybern (2015) 1.54

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53

A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer (2013) 1.53

Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52

Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52

Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.52

A platform for accurate mass and time analyses of mass spectrometry data. J Proteome Res (2007) 1.52

The word "cancer": how language can corrupt thought. BMJ (2013) 1.51

Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst (2010) 1.51

Monster cells in malignant melanoma. Am J Dermatopathol (2005) 1.49

Alcohol drinking, cigarette smoking, and risk of colorectal adenomatous and hyperplastic polyps. Am J Epidemiol (2008) 1.47

Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol (2003) 1.46

Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45

A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45

Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol (2005) 1.44

A population approach to precision medicine. Am J Prev Med (2012) 1.44

Steps to ensure accuracy in genotype and SNP calling from Illumina sequencing data. BMC Genomics (2012) 1.44

Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res (2010) 1.43

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42

Quantitative metrics in clinical radiology reporting: a snapshot perspective from a single mixed academic-community practice. Magn Reson Imaging (2012) 1.42

Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40

Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med (2004) 1.40

Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol (2007) 1.40

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40

Functional genomic screens identify CINP as a genome maintenance protein. Proc Natl Acad Sci U S A (2009) 1.38

Finding the lost treasures in exome sequencing data. Trends Genet (2013) 1.36

Differential label-free quantitative proteomic analysis of Shewanella oneidensis cultured under aerobic and suboxic conditions by accurate mass and time tag approach. Mol Cell Proteomics (2006) 1.36

A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res (2003) 1.36

Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep (2010) 1.36

The effect of strand bias in Illumina short-read sequencing data. BMC Genomics (2012) 1.34

A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis (2012) 1.32

Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res (2003) 1.32

Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med (2005) 1.32